Keros Therapeutics, Inc. (KROS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Keros Therapeutics, Inc. on November 7, 2023. The filing serves as a Regulation FD disclosure to announce upcoming corporate presentations by the Company's President and Chief Executive Officer, Jasbir Seehra, at major healthcare industry conferences.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of upcoming events and does not contain financial statements or operational metrics.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces scheduled investor relations activities.
Guidance, Outlook, and Management Commentary
Management has scheduled the following presentations to discuss the Company's business:
- Stifel 2023 Healthcare Conference: Tuesday, November 14, 2023, at 2:25 p.m. Eastern time.
- Piper Sandler 35th Annual Healthcare Conference: Wednesday, November 29, 2023, at 2:30 p.m. Eastern time.
The press release accompanying this filing is furnished as Exhibit 99.1. The information in this report is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the date and time of the Stifel and Piper Sandler conference presentations to access management commentary.
- Review the attached press release (Exhibit 99.1) for specific details on the presentation agenda.
- Note that this 8-K contains no financial data; investors should refer to the most recent 10-Q or 10-K for financial metrics.